Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial)

HIV Molecular Research Group, School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland.
HIV Medicine (Impact Factor: 3.99). 05/2011; 12(10):602-9. DOI: 10.1111/j.1468-1293.2011.00934.x
Source: PubMed

ABSTRACT The aim of the study was to evaluate the predictive value of clinical and molecular risk factors, including peripheral blood mononuclear cell (PBMC) mitochondrial DNA (mtDNA) and mitochondrial RNA (mtRNA), for the development of lactic acidosis (LA) and symptomatic hyperlactataemia (SHL).
In a substudy of a large multicentre, randomized trial of three antiretroviral regimens, all containing didanosine (ddI) and stavudine (d4T), in antiretroviralnaïve, HIV-1-infected patients, patients with LA/SHL ('cases') were compared with those without LA/SHL in a univariate analysis, with significant parameters analysed in a multivariate model. In a molecular substudy, PBMC mtDNA and mtRNA from cases and matched controls at baseline and time of event were examined.
In 911 subjects followed for a median of 192 weeks, 24 cases were identified (14 SHL and 10 LA). In univariate analysis, cases were more likely to be female (P=0.05) and to have a high body mass index (BMI) (P=0.02). In multivariate analyses, only BMI remained an independent predictor of the development of LA/SHL (P=0.03). Between cases and controls there was no significant difference in mtDNA copy number at baseline (389 vs. 411 copies/cell, respectively; P=0.60) or at time of event (329 vs. 474 copies/cell, respectively; P=0.21), in the change in mtDNA copy number from baseline to event (-65 vs. +113 copies/cell, respectively; P=0.12), in mtRNA expression at baseline or time of event, or in the change in mtRNA expression from baseline to event.
The development of LA/SHL was associated with increased BMI, but PBMC mtDNA and mtRNA did not predict LA/SHL. This demonstrates the ineffectiveness of routine measurement of PBMC mtDNA in patients on ddI and d4T as a means of predicting development of LA/SHL.

5 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE:: No randomised study has prospectively followed subcutaneous adipose tissue mitochondrial DNA (mtDNA) changes when starting thymidine nucleoside reverse transcriptase inhibitors (tNRTI). DESIGN:: The MEDICLAS study randomised HIV+, treatment-naïve male subjects to start lopinavir/ritonavir (LPVr) with either zidovudine/lamivudine (AZT/3TC) or NVP. METHODS:: Regional body fat was assessed by DXA and abdominal CT at months 0, 3, 12, 24 and 36. In a molecular substudy, SAT biopsies were taken, with mtDNA quantified by quantitative PCR. Data was analysed using repeated measures linear regression analyses. RESULTS:: Of 50 subjects recruited (23 to LPVr/AZT/3TC) 48 started therapy, and 37 subjects (19 on LPVr/AZT/3TC) enrolled in the substudy. At 36 months, the LPVr/AZT/3TC group had significantly lower limb fat (6.4kg(0.26) versus 7.3kg(0.31), P = 0.017) and a trend towards lower abdominal SAT compared to the LPVr/NVP group (131 cm(6.86) versus 146 cm(6.33), P = 0.097).Over 36 months, mtDNA declined in the LPVr/AZT/3TC group (mtDNA region 1: -190(95) copies/cell, P = 0.053, region 2: -269(106) copies/cell, P = 0.016) but not within the LPVr/NVP group (Region 1: +28 (99) copies/cell, P = 0.78, Region 2: +51 (111) copies/cell, P = 0.65, between-group difference P < 0.01 for both measurements). mtDNA was significantly lower in the LPVr/AZT/3TC group at 36 months. CONCLUSIONS:: This is the first randomised study to prospectively demonstrate reductions in SAT mtDNA in patients initiating AZT/3TC-containing ART but not in those initiating NRTI-sparing ART containing NVP and PI. That reductions in SAT mtDNA were also accompanied by lower limb fat suggests that use of ART not containing AZT/3TC may help prevent development of peripheral lipoatrophy.
    AIDS (London, England) 08/2012; 26(17). DOI:10.1097/QAD.0b013e328358b279 · 5.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antiretroviral drugs (ARVs) are indispensable in the treatment and prevention of human immunodeficiency virus infection. Although their use before, during and after pregnancy is considered safe for mother and child, there are still lingering concerns about their long-term health consequences and the ramifications of their effects on lipid, glucose, intermediary and mitochondrial metabolism. This article reviews the known effects of ARVs on macromolecular and mitochondrial metabolism as well as the potential maternal, fetal, neonatal and adult health risks associated with abnormal energy metabolism during gestation. Recommendations about enhanced monitoring for these risks in affected populations are being provided.
    Seminars in Fetal and Neonatal Medicine 11/2012; 18(1). DOI:10.1016/j.siny.2012.10.005 · 3.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondrial damage is implicated in highly active antiretroviral therapy (HAART) toxicity. HIV infection also causes mitochondrial toxicity (MT). Differentiating between the two is critical for HIV management. Our objective was to test the utility of the Mitochondrial Disease Criteria (MDC) and the Enquête Périnatale Française (EPF) to screen for possible HAART related MT in HIV-infected children in Ghana. The EPF and MDC are compilations of clinical symptoms, or criteria, of MT: a (+) score indicates possible MT. We applied these criteria retrospectively to 403 charts of HIV-infected children. Of those studied, 331/403 received HAART. Comparing HAART exposed and HAART naïve children, the difference in EPF score, but not MDC, approached significance (P = 0.1). Young age at HIV diagnosis or at HAART initiation was associated with (+) EPF (P ≤ 0.01). Adherence to HAART trended toward an association with (+) EPF (P = 0.09). Exposure to nevirapine, abacavir, or didanosine increased risk of (+) EPF (OR = 3.55 (CI = 1.99-6.33), 4.76 (2.39-9.43), 4.93 (1.29-18.87)). Neither EPF nor MDC identified a significant difference between HAART exposed or naïve children regarding possible MT. However, as indicators of HAART exposure are associated with (+) EPF, it may be a candidate for prospective study of possible HAART related MT in resource-poor settings.
    AIDS research and treatment 03/2013; 2013:249171. DOI:10.1155/2013/249171
Show more


5 Reads